SCHEMBL20074710

SCHEMBL20074710

CC(C)n1cncc1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.43
DYRK1A Q13627 2/20 0.43
CLK2 P49760 1/20 0.43
CLK3 P49761 1/20 0.43
CNR1 P21554 1/20 0.42
HSD11B1 P28845 1/20 0.39
SCN10A Q9Y5Y9 1/20 0.37
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAA1 Q13131 1/20 0.37
PRKAG3 Q9UGI9 1/20 0.37
PRKAG2 Q9UGJ0 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
JAK2 O60674 1/20 0.36
MAP4K4 O95819 1/20 0.36
CYP3A4 P08684 2/20 0.35
CYP17A1 P05093 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
P4HTM Q9NXG6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20074766 0.89 CLK2 (0.41) GSK3BDYRK1ACLK2CLK3SCN10A
SCHEMBL30089420 0.89 CLK2 (0.41) GSK3BDYRK1ACLK2CLK3SCN10A
SCHEMBL20074802 0.88 P2RY14 (0.45) GSK3BDYRK1ACLK2CLK3PRKAB2
SCHEMBL20074817 0.86 GSK3B (0.52) GSK3BDYRK1ACLK2CLK3CNR1
SCHEMBL20074608 0.85 CNR1 (0.43) GSK3BDYRK1ACNR1HSD11B1SCN10A
SCHEMBL20074641 0.83 CNR1 (0.42) GSK3BDYRK1ACNR1HSD11B1SCN10A
SCHEMBL22678433 0.81 AKT1 (0.41) GSK3BDYRK1ACLK2CLK3CYP3A4
SCHEMBL19641928 0.80 CNR1 (0.42) CNR1HSD11B1SCN10APRKAB2PRKAG1
SCHEMBL18496602 0.78 SCN10A (0.46) CNR1HSD11B1SCN10AJAK2MAP4K4
SCHEMBL18496661 0.78 DYRK1A (0.52) DYRK1ACNR1SCN10AEGLN1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN claimed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP claimed
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
WO-2018069362-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors SLC1A1, SLC1A3, SLC1A2 GSK3B 2961/4885DYRK1A 3045/4885CLK2 2424/4885
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS SLC1A1, SLC1A3, SLC1A2 GSK3B 2961/4885DYRK1A 3045/4885CLK2 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.